Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting
JINAN, China, March 4, 2024 /PRNewswire/ — The European Society of Gynecological…
YCYW's Inaugural International Education Symposium: An Overwhelming Success Presenting Chinese and International Thought Leaders from the Education Sector
HONG KONG, March 4, 2024 /PRNewswire/ — The International Education Symposium, "Transforming…